MYB and breast carcinoma: Note that the overall effectiveness of CDK9i in killing ER+ve/MYB+ve breast cancer cells is unlikely to be limited to 50% because (a) longer treatment increases the proportion of dead cells measured, and (b) the FACS-based assays used here are likely to underestimate the true proportion of dead cells (data not shown).